
BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

How microplastic particles get into the body
Microplastic particles exposed to freshwater or saltwater environments for several weeks are about ten times more likely than pristine particles to...

Vifor Pharma in US$100m licence deal with Cara Therapeutics
Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Transgene reports clinical results of TG4001 plus avelumab
Combination of TG4001 and Merck KGaA’s checkpoint inhibitor avelumab demonstrated anti-tumour activity in patients with previously treated recurrent...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

EU COVID-19 antibody ready for clinical trials
CORAT Therapeutics reports the start of production of the first batch of the therapeutic human COVID-19 antibody COR-101 for Phase I testing....